PRMT1 and neoplasm: Both knockdown and pharmacological inhibition of PRMT1 in PATC53 cells (PDAC patient-derived cells) results in the reduction of cell proliferation and colony formation in vitro as well as reduced tumor volume in vivo, with a significant decrease in cellular and tissue ADMA levels and an increase in the MMA levels.